Dynavax’s Heplisav Vaccine Works on Hepatitis B, FDA Says

Dynavax Technologies Corp.’s Heplisav vaccine works against the contagious liver disease hepatitis B, Food and Drug Administration staff said. The company’s shares jumped the most in about 14 months on the report.

To continue reading this article you must be a Bloomberg Professional Service Subscriber.